Charles River Laboratories (CRL) Tops Q3 EPS by 15c
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $273.00 -1.92%
Revenue Growth %: -4.3%
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.53, $0.15 better than the analyst estimate of $1.38. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $567.79 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.87-$5.97, versus the consensus of $5.92.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- RH (RH) Tops Q2 EPS by $2.31
- Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
